Cargando…
Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile
In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained r...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176985/ https://www.ncbi.nlm.nih.gov/pubmed/32337506 http://dx.doi.org/10.1016/j.jvacx.2020.100060 |
_version_ | 1783525119334809600 |
---|---|
author | Monath, Thomas P. Kortekaas, Jeroen Watts, Douglas M. Christofferson, Rebecca C. Desiree LaBeaud, Angelle Gowen, Brian Peters, Clarence J. Smith, Darci R. Swanepoel, Robert Morrill, John C. Ksiazek, Thomas G. Pittman, Phillip R Bird, Brian H. Bettinger, George |
author_facet | Monath, Thomas P. Kortekaas, Jeroen Watts, Douglas M. Christofferson, Rebecca C. Desiree LaBeaud, Angelle Gowen, Brian Peters, Clarence J. Smith, Darci R. Swanepoel, Robert Morrill, John C. Ksiazek, Thomas G. Pittman, Phillip R Bird, Brian H. Bettinger, George |
author_sort | Monath, Thomas P. |
collection | PubMed |
description | In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained rigid requirements to protect against genomic reassortment of live, attenuated vaccines (LAVs) with wild-type RVF virus (RVFV), which place undue constraints on development and regulatory approval of LAVs. We review the current LAVs in use and in development, and conclude that there is no evidence that reassortment between LAVs and wild-type RVFV has occurred during field use, that such a reassortment event if it occurred would have no untoward consequence, and that the TPPs should be revised to provide a more balanced assessment of the benefits versus the theoretical risks of reassortment. |
format | Online Article Text |
id | pubmed-7176985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-71769852020-04-24 Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile Monath, Thomas P. Kortekaas, Jeroen Watts, Douglas M. Christofferson, Rebecca C. Desiree LaBeaud, Angelle Gowen, Brian Peters, Clarence J. Smith, Darci R. Swanepoel, Robert Morrill, John C. Ksiazek, Thomas G. Pittman, Phillip R Bird, Brian H. Bettinger, George Vaccine X Review In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained rigid requirements to protect against genomic reassortment of live, attenuated vaccines (LAVs) with wild-type RVF virus (RVFV), which place undue constraints on development and regulatory approval of LAVs. We review the current LAVs in use and in development, and conclude that there is no evidence that reassortment between LAVs and wild-type RVFV has occurred during field use, that such a reassortment event if it occurred would have no untoward consequence, and that the TPPs should be revised to provide a more balanced assessment of the benefits versus the theoretical risks of reassortment. Elsevier 2020-04-09 /pmc/articles/PMC7176985/ /pubmed/32337506 http://dx.doi.org/10.1016/j.jvacx.2020.100060 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Monath, Thomas P. Kortekaas, Jeroen Watts, Douglas M. Christofferson, Rebecca C. Desiree LaBeaud, Angelle Gowen, Brian Peters, Clarence J. Smith, Darci R. Swanepoel, Robert Morrill, John C. Ksiazek, Thomas G. Pittman, Phillip R Bird, Brian H. Bettinger, George Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title | Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title_full | Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title_fullStr | Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title_full_unstemmed | Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title_short | Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile |
title_sort | theoretical risk of genetic reassortment should not impede development of live, attenuated rift valley fever (rvf) vaccines commentary on the draft who rvf target product profile |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176985/ https://www.ncbi.nlm.nih.gov/pubmed/32337506 http://dx.doi.org/10.1016/j.jvacx.2020.100060 |
work_keys_str_mv | AT monaththomasp theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT kortekaasjeroen theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT wattsdouglasm theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT christoffersonrebeccac theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT desireelabeaudangelle theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT gowenbrian theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT petersclarencej theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT smithdarcir theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT swanepoelrobert theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT morrilljohnc theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT ksiazekthomasg theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT pittmanphillipr theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT birdbrianh theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile AT bettingergeorge theoreticalriskofgeneticreassortmentshouldnotimpededevelopmentofliveattenuatedriftvalleyfeverrvfvaccinescommentaryonthedraftwhorvftargetproductprofile |